rs1152003 — PPARG

PPARG 3'-flanking region variant — the G allele independently tags a PPARG regulatory haplotype associated with altered TZD (thiazolidinedione) insulin-sensitizing drug response and modified type 2 diabetes risk in lifestyle intervention cohorts

See your personal result for PPARG

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PPARG rs1152003 — A Regulatory Signal in the 3' Flank

The PPARG gene encodes Peroxisome Proliferator-Activated Receptor Gamma11 Peroxisome Proliferator-Activated Receptor Gamma
PPARγ is a nuclear transcription factor and the master regulator of adipocyte differentiation and insulin sensitization. It is the molecular target of thiazolidinedione (TZD) diabetes drugs, the protein that coordinates fat cell formation, whole-body insulin sensitivity, and adipokine secretion. rs1152003 sits in the 3'-flanking region of PPARG — not within a coding exon, but in a regulatory zone that can influence gene expression levels and transcript stability. Unlike the more-studied PPARG Pro12Ala (rs1801282), rs1152003 shows no linkage disequilibrium with other PPARG variants, making it an independent signal in the gene's regulatory landscape.

The Mechanism

Variants in the 3' untranslated and flanking regions of genes can affect mRNA stability, polyadenylation, and microRNA binding — all of which influence how much functional PPARγ protein a cell ultimately produces. Because PPARγ protein levels directly determine the degree of insulin sensitization in adipose tissue and skeletal muscle, even modest alterations in expression can shift insulin sensitivity trajectories. rs1152003 was specifically noted to fall outside of any haplotype block in the PPARG gene structure, suggesting it tags a unique functional element rather than riding on another variant's biological effect.

The Evidence

The strongest evidence comes from the Wolford et al. 200522 Wolford et al. 2005
Wolford JK et al. Sequence variation in PPARG may underlie differential response to troglitazone. Diabetes 2005;54(11): 3195-3201 pharmacogenetic study. Sequencing approximately 40 kb of PPARG in 93 Hispanic women with prior gestational diabetes who were randomized to troglitazone or placebo, the team identified 131 variants and tested each for association with insulin sensitivity improvement. rs1152003 emerged as the strongest single-variant predictor: the G allele carried an odds ratio of 2.19 (95% CI: 1.13–4.28, P = 0.020) for improved insulin sensitivity on troglitazone. The GG genotype, however, showed a paradoxical attenuation — suggesting a non-linear (possibly recessive) pharmacological dose-response. rs1152003 was not in linkage disequilibrium with any other significant PPARG variant, confirming it as an independent pharmacogenomic signal.

In the lifestyle intervention setting, the Lindi/Kilpeläinen et al. 200833 Lindi/Kilpeläinen et al. 2008
Kilpeläinen TO et al. SNPs in PPARG associate with type 2 diabetes and interact with physical activity. Med Sci Sports Exerc 2008;40(1):25-33 study genotyped rs1152003 among seven PPARG variants in 479 overweight individuals with impaired glucose tolerance (IGT) from the Finnish Diabetes Prevention Study (DPS), followed for 4.2 years. rs1152003 interacted with the study arm assignment on T2D conversion (P = 0.027) and tended to increase diabetes risk specifically in the lifestyle intervention group (P = 0.050). This genotype-by-intervention interaction is notable but was not accompanied by the strong physical activity modifiability that characterized rs17036314 in the same cohort.

Bone metabolism has also been studied: Harsløf et al. 201144 Harsløf et al. 2011
Harsløf T et al. Polymorphisms of the peroxisome proliferator-activated receptor γ gene are associated with osteoporosis. Osteoporos Int 2011;22:2655–2666 found that rs1152003 interacted with body weight to influence BMD across all skeletal sites in two independent Danish cohorts (n = 2,525), with variant-allele homozygotes showing decreased BMD. PPARγ activation promotes adipogenic differentiation of mesenchymal stem cells at the expense of osteogenesis, so PPARG regulatory variants plausibly affect bone density alongside metabolic phenotypes.

The evidence base is relatively small and based predominantly on single cohorts — evidence level is therefore rated as emerging.

Practical Actions

For G allele carriers, the primary actionable implication is pharmacological: if TZD-class diabetes drugs (pioglitazone or rosiglitazone) are ever considered, the G allele at rs1152003 was associated with greater insulin-sensitizing response in the original pharmacogenetic study. This is worth noting to a prescriber. Bone health monitoring is relevant for GG homozygotes given the BMD interaction data, particularly in the context of body weight — lower-weight GG carriers showed the largest BMD decreases in the Harsløf cohorts.

Interactions

rs1152003 is genetically independent from other PPARG variants — it does not travel with the well-studied rs1801282 (Pro12Ala) or the DPS-associated rs17036314. However, all PPARG variants ultimately converge on PPARγ protein availability and transcriptional activity. Carriers of multiple PPARG variants (rs1801282 + rs17036314 + rs1152003) may experience compounded alterations in PPARγ-driven insulin sensitization, though no published study has formally assessed the three-way combination. PPARD rs2016520 and PPARGC1A rs8192678 (Gly482Ser) operate in the same transcriptional network and could compound further.

Drug Interactions

pioglitazone dose_adjustment literature
rosiglitazone dose_adjustment literature
troglitazone increased_efficacy literature

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal

Common PPARG 3'-flanking genotype — standard regulatory profile

The CC genotype at rs1152003 is the population-typical configuration of this PPARG 3'-flanking regulatory region. In Wolford et al. 2005 (PMID 16249460), CC carriers showed the reference level of insulin sensitivity improvement on troglitazone — not an absence of response, but the baseline expectation. In the Finnish DPS (Lindi et al. 2008, PMID 18091023), no elevated T2D risk was associated with the CC genotype. For bone health, CC homozygotes were not identified as an at-risk subgroup in the Harsløf 2011 Danish cohort study.

CG One G Allele Intermediate

One G allele — modestly altered PPARG 3' regulatory signal

The CG genotype places one copy of the rs1152003 G allele at this PPARG 3'-flanking locus. Because rs1152003 is not in LD with any other PPARG variant, this represents a distinct regulatory element. Wolford et al. 2005 identified the G allele in a dominant or codominant pattern for TZD response; the OR 2.19 (95% CI 1.13–4.28) was computed across all G carriers (CG + GG) compared to CC in a dominant model. For bone health, the BMD interactions noted by Harsløf 2011 were most pronounced in the GG homozygous group; CG carriers represent an intermediate position.

GG Homozygous G High Risk

Two G alleles — distinct PPARG regulatory profile, complex TZD response

The GG genotype at rs1152003 represents homozygosity for the minor PPARG 3'-flanking allele. The pharmacogenetic paradox observed by Wolford 2005 — where G carriers overall had improved TZD response (OR 2.19) but GG homozygotes showed reduced improvement compared to CG carriers when analyzed separately in a recessive model — suggests a complex dose-response curve. One possible explanation is that altering PPARG 3'-flanking regulatory function produces a beneficial effect in one copy but overshoots an optimal range with two copies. For bone health, Harsløf 2011 found rs1152003 interacted with body weight on BMD across all skeletal sites in both Danish cohorts studied (P ≤ 0.07), with GG homozygotes showing decreased BMD (P ≤ 0.02 in AROS, P ≤ 0.03 in DOPS). Given PPARG's role in directing mesenchymal stem cells toward fat cells rather than bone cells, PPARG regulatory variants can plausibly influence bone density alongside metabolic phenotypes. The overall evidence for clinical action remains emerging given small cohort sizes.